Varlilumab(一种新型首创性激动型抗CD27抗体)在晚期实体瘤患者中的安全性与活性
这项首次人体、剂量递增与扩展研究在晚期实体瘤患者中评估了Varlilumab的安全性、药理学与抗肿瘤活性。剂量递增至10 mg/kg耐受良好,未确定最大耐受剂量;仅1例在1.0 mg/kg剂量水平出现剂量限制性毒性(3级短暂无症状性低钠血症);1例转移性肾细胞癌患者获部分缓解(缩小78%,无进展生存期>2.3年)。
要点
- 剂量递增至10 mg/kg耐受良好,未确定最大耐受剂量。
- 仅1例在1.0 mg/kg剂量水平发生剂量限制性毒性:3级短暂无症状性低钠血症。
- 1例转移性肾细胞癌患者获部分缓解(缩小78%,无进展生存期>2.3年)。
核心结论
- Varlilumab剂量递增至10 mg/kg耐受良好,未确定最大耐受剂量。
- Varlilumab具有生物学和临床活性。
研究设计与样本
- 首次人体、剂量递增与扩展研究,采用3+3剂量递增设计,递增阶段n=25。
- 递增阶段患者接受单次静脉注射Varlilumab(0.1、0.3、1.0、3.0或10 mg/kg),观察28天,随后根据肿瘤反应接受最多五个多剂量周期(每周一次,共4周)。
- 扩展队列在3.0 mg/kg剂量下开展,纳入黑色素瘤患者(n=16)和肾细胞癌患者(n=15)。
- 主要目标为评估安全性和最大耐受剂量及最佳生物学剂量;次要目标为评估药代动力学、药效学和临床抗肿瘤活性。
主要发现
- Varlilumab暴露在各剂量组间呈线性且剂量成比例。
- 仅1例患者在1.0 mg/kg剂量水平发生剂量限制性毒性:3级短暂无症状性低钠血症。
- 治疗相关不良事件严重程度一般为1级或2级。
- 在所有剂量水平均观察到与CD27刺激一致的生物学活性证据:趋化因子诱导、T细胞刺激、调节性T细胞耗竭。
- 1例转移性肾细胞癌患者获部分缓解(缩小78%,无进展生存期>2.3年);8例患者疾病稳定>3个月,其中1例转移性肾细胞癌患者无进展生存期>3.9年。
关键数值与推荐
- 剂量递增水平:0.1、0.3、1.0、3.0、10 mg/kg静脉注射。
- 扩展队列剂量:3.0 mg/kg,黑色素瘤n=16,肾细胞癌n=15。
- 剂量限制性毒性:1例在1.0 mg/kg剂量水平发生3级短暂无症状性低钠血症。
- 部分缓解:1例转移性肾细胞癌患者缩小78%,无进展生存期>2.3年。
- 疾病稳定>3个月:8例患者,其中1例转移性肾细胞癌患者无进展生存期>3.9年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors. Methods In a 3 + 3 dose-escalation design (n = 25), patients received a single dose of varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg intravenously) with a 28-day observation, followed by up to five multidose cycles (one dose per week for 4 weeks), depending on tumor response. Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15). Primary objectives were to assess the safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab. Results Exposure to varlilumab was linear and dose proportional across dose groups. Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg dose level. Treatment-related adverse events were generally grade 1 or 2 in severity. Evidence of biologic activity consistent with CD27 stimulation-chemokine induction, T-cell stimulation, regulatory T cell depletion-was observed at all dose levels. A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free survival > 2.3 years). Eight patients experienced stable disease > 3 months, including a patient with metastatic RCC with progression-free survival of > 3.9 years. Conclusion Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose. Varlilumab was biologically and clinically active.
引用
- Burris HA, Infante JR, Ansell SM, et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017. PMID: 28463630. doi:10.1200/JCO.2016.70.1508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。